Hisar, Oct 11: Self-styled godman Rampal was on Thursday found guilty by a court in Hisar in two murder cases.
Additional District and Sessions Judge, Hisar, D R Chaliya, held Rampal and some of his followers guilty in these cases. The quantum of punishment will be pronounced on October 16 and 17.
Rampal and 27 of his followers were charged with murder and wrongful confinement after four women and a child were found dead in his Satlok Ashram in Barwala town in Hisar on November 19, 2014.
May 27: At a time when India is struggling with the deadly coronavirus, huge swarms of locusts in many states has bought nightmares to the farmers.
Experts warn of extensive crop losses if authorities fail to curb the fast-spreading swarms by June when monsoon rains spur rice, cane, corn, cotton, and soybean sowing.
Locusts entered India after traveling from Africa through Yemen, Iran and Pakistan.
After massive devastation in Pakistan, t swarms of locusts entered India through Rajasthan and Gujarat. The number is so large that the farmers and authorities are feeling helpless in tackling the threat.
The situation has become more alarming as the locusts is spreading across the country at an extremely fast rate. After badly affecting the crops in Rajasthan, Gujarat, Maharashtra, and Madhya Pradesh, the swarm of locust have now entered Uttar Pradesh.
In Rajasthan alone, the locust attack has damaged 5 lakh hectares of crop and nearly 17 districts of Madhya Pradesh have also seen their terror. Earlier from May 2019 to February 2020, too, the locust swarms entered India several times.
Speaking on the current situation, Dr Ram Pravesh, District Agricultural Officer, Agra, Uttar Pradesh said the Department of Agriculture is working with farmers in dealing with the situation. He urged the farmers to inform their Mandal Krishi Adhikari if they require any help.
India's largest-ever locust attack was in 1993 when more than three lakh hectares of cultivated land were completely destroyed.
Earlier in 2020, farmers salvaged their wheat and oilseed crops from a previous locust scourge.
Apr 24: Kerala Chief Minister Pinarayi Vijayan on Friday sought Prime Minister Narendra Modi's intervention in bringing bodies of Keralites who died in the Gulf countries due to non-COVID-19 reasons to the state without any delay for performing last rites in their home towns.
In a letter, he wanted Modi to direct Indian embassies to issue necessary clearances without seeking individual approvals from the Ministry of Home Affairs and avoid any delay so that the remains reach Kerala early. It has been learnt that a 'clearance certificate' from the Indian embassies concerned was required to process the application for bringing home the bodies.
The embassies are insisting on production of no-objection certificate from the Union Ministry of Home Affairs, he said in the letter, a copy of which was released to the media here on Friday. The Centre had already agreed that in case the deaths are not COVID related, such certificates are not necessary.
The bodies are now being brought in the cargo planes as passenger flights are not being operated due to the lockdown. Chief Minister said he had received several grievances from the NRKs in Gulf Cooperation Council (GCC) countries on the delay in bringing home the bodies of those who died there. "They are already under tremendous stress and anxiety due to the lockdown imposed in those countries and the consequent stoppage of international flights", Vijayan said.
The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed Covid-19 vaccine candidate in the country.
Government officials said that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on Covid-19.
"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.
"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.
As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, 'Covishield', on healthy adults in India, the officials said.
Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.
The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.
The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.
According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.
"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults," the official said.
The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for Covid-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine.
Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.
To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca.
Comments
Thank God. Hope that all criminals would go to jail.
Add new comment